Six months of breast cancer treatment ‘could be as effective as 12’ in some women with early stage disease

The American Cancer Society (ACS) estimated that, in 2018, there will be more than 234,000 new cases of lung cancer and over 154,000 deaths to it.

Each year, more people die from lung cancer than they do from breast, prostate, and colon cancer combined.

One reason that the prognosis for lung cancer is so poor is that only around 20 percent of cases respond to immunotherapies. This is significantly lower than other cancers.

Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) in Germany are trying to work out what it is about lung cancer that makes immune-based treatments so hit and miss.